Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis are closely linked to dysfunction of the blood–brain barrier (BBB)—a protective layer that regulates what enters and exits the brain. This review explores how cannabinoids interact with the BBB and the endocannabinoid system, which plays a key role in maintaining brain balance. Researchers highlight that in neurodegenerative conditions, the BBB often becomes weakened or “leaky,” allowing harmful molecules and inflammation to damage brain tissue.

The article explains that cannabinoids may help protect and stabilize the BBB by reducing inflammation and regulating immune responses within the brain. Through interactions with cannabinoid receptors and related signaling pathways, cannabinoids appear to limit the release of inflammatory molecules and support the integrity of blood vessels in the brain. Some evidence also suggests cannabinoids may influence transport mechanisms at the BBB, potentially improving how nutrients and signaling molecules move while restricting harmful substances.

Overall, the review concludes that cannabinoids show promise as multi-target compounds that could address several aspects of neurodegeneration at once, including inflammation, oxidative stress, and BBB dysfunction. However, most of the current evidence comes from preclinical and early-stage studies, and more human clinical research is needed to determine safety, effectiveness, and how these mechanisms translate into real-world treatments for neurological diseases.

Source:
Ben-Shabat S, et al. Cannabinoids, the Blood–Brain Barrier, and Neurodegeneration: Mechanisms, Dysregulation, and Therapeutic Perspectives. National Library of Medicine (NIH):
https://pmc.ncbi.nlm.nih.gov/articles/PMC12938789/